Drug Guidance for Subsidy 01/06/2023 Romosozumab and teriparatide for treating osteoporosis NRThe Ministry of Health’s Drug Advisory Committee has not recommended: Romosozumab or teripa... See all × 01/06/2023 Romosozumab and teriparatide for treating osteoporosis NRThe Ministry of Health’s Drug Advisory Committee has not recommended: Romosozumab or teriparatide for inclusion on the MOH List of Subsidised Drugs for treating postmenopausal women with osteoporosis who are at high risk for fracture; and Teriparatide for inclusion on the MOH List of Subsidised Drugs for treating men with primary or hypogonadal osteoporosis who are at high risk for fracture, or patients with glucocorticoid-induced osteoporosis who are at high risk for fracture due to uncertain extent of clinical benefit and unfavourable cost-effectiveness compared with subsidised alternatives.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Evenity Injection, Solution 105 mg/1.17 mL Alexandra Hospital Changi General Hospital KK Women's and Children's Hospital National University Hospital Sengkang General Hospital Singapore General Hospital
SUBCUTANEOUS Select a brand starting with the letter: E EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML [SIN16208P]